Quotables
"Without question, the greatest invention in the history of mankind is beer. Oh, I grant you that the wheel was also a fine invention, but the wheel does not go nearly as well with pizza."
Dave Barry
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183340 | GLP-1 pegylated compounds The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1... | 05/22/2012 |
| 8003102 | Anti-CXCR4 antibodies The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogen... | 08/23/2011 |
| 7989585 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/02/2011 |
| 7968686 | Glucagon receptor antagonists The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that... | 06/28/2011 |
| RE42274 | Cyclic peptide CXCR4 antagonists Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection. ... | 04/05/2011 |
| 7901679 | Humanized anti-ghrelin antibodies Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, includ... | 03/08/2011 |
| 7897573 | Selective VPAC2 receptor peptide agonists The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. ... | 03/01/2011 |
| 7892546 | Anti-CXCR4 antibodies The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogen... | 02/22/2011 |
| 7872102 | Anti-IL-23 antibodies The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment... | 01/18/2011 |
| 7714120 | Humanized anti-IL-1 beta antibodies The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values),... | 05/11/2010 |
| 7691813 | Cyclic peptide CXCR4 antagonists Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection. ... | 04/06/2010 |
| RE41133 | Glucagon-like peptide-1 crystals The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are ... | 02/16/2010 |
| 7598222 | Process for solubilizing glucagon-like peptide 1 compounds Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to for... | 10/06/2009 |
| 7582608 | Selective VPAC2 receptor peptide agonists The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. ... | 09/01/2009 |
| 7557183 | Polyethylene glycol linked GLP-1 compounds The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGyla... | 07/07/2009 |
